Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE
  4. Optimizing Outcomes in AAD in Community PCP and LTC Clinics

Optimizing Outcomes in AAD in Community PCP and LTC Clinics

Burden Beyond the Patient: AAD's Impact on Patients and Caregivers

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Related
Comments
  • Overview

    This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    C. Brendan Montano, MD
    Director, Principal Investigator 
    CT Clinical Research
    Cromwell, CT

    Dr. Montano has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: AbbVie, Autobahn, Axsome, Biohaven, Boehringer Ingelheim, Cassava, Click, Eli Lilly, Idorsia, Intra-Cellular, Janssen, Jazz, Neurocrine, Otsuka, Relmada, Sage Therapeutics, Supernus, Tonix
    Consulting Fees: AbbVie, Axsome, Boehringer Ingelheim, Corium, Eisai, Idorsia, Intra-Cellular, Janssen, Neurocrine, Otsuka, Sage/Biogen, Supernus

    Anton P. Porsteinsson, MD
    Professor of Psychiatry, Neurology, Neuroscience, and Medicine
    University of Rochester School of Medicine and Dentistry
    Rochester, NY

    Dr. Porsteinsson has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Alector, Athira, Biogen, Cassava, DOD, Eisai, Eli Lilly, Genentech/Roche, NIA, NIMH, Vaccinex
    Consulting Fees: Acadia Pharmaceuticals, Athira, Axsome, Biogen, BMS, Cognitive Research Corp, Eisai, IQVIA, Lundbeck, Novartis, ONO Pharmaceuticals, Otsuka, WCG, WebMD, Xenon

    Reviewers/Content Planners/Authors:

    • Tim Person has nothing to disclose.
    • Rosanne Strauss has nothing to disclose.
    • Canan Schumann has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the prevalence and disease burden associated with agitation in Alzheimer’s disease (AAD) among PCPs and caregivers 
    • Recognize the subtle signs and symptoms of agitation in Alzheimer’s disease (AAD) as well as the clinically validated screening tools that are required for an early and rapid diagnosis 
    • Demonstrate effective collaboration and communication within a multidisciplinary team of PCPs, caregivers, and specialists to improve the management of AAD
    • Understand the pathophysiology of AAD in order to better design personalized treatment approaches for patients
    • Compare and contrast the safety and efficacy of off-label medications used to manage AAD that carry significant black box warnings
    • Develop evidence-based treatment strategies to incorporate FDA-approved and emerging therapeutics into AAD management 
  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians and neurologists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with Alzheimer's disease.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until October 15, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.25 contact hours/ .125 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-116-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME, LLC employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by an independent educational grant from Otsuka America Pharmaceutical Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule11 Nov 2024